1081-05-6 Usage
Uses
Used in Pharmaceutical Industry:
5-CHLORO-1H-INDAZOLE-3-CARBOXYLIC ACID ETHYL ESTER is used as a key intermediate for the synthesis of bioactive molecules, primarily due to its structural properties that facilitate the creation of potential drug candidates. Its utility in this industry stems from its ability to be incorporated into various chemical entities that target specific diseases or conditions, thereby enhancing the therapeutic options available.
Used in Medicinal Chemistry Research:
As a component in medicinal chemistry, 5-CHLORO-1H-INDAZOLE-3-CARBOXYLIC ACID ETHYL ESTER is utilized for its potential to form new compounds with biological activity. Researchers leverage its chemical properties to design and develop novel therapeutic agents, contributing to the advancement of medical treatments.
Used in Drug Discovery:
In the realm of drug discovery, 5-CHLORO-1H-INDAZOLE-3-CARBOXYLIC ACID ETHYL ESTER is employed as a valuable chemical entity in the screening and development of new pharmaceuticals. Its inclusion in compound libraries aids in the identification of promising candidates that can be further optimized for clinical efficacy and safety.
While the provided materials do not specify particular applications or industries beyond the general pharmaceutical context, the compound's role as a building block and intermediate in medicinal chemistry and drug discovery is underscored, highlighting its broad utility across various stages of pharmaceutical research and development.
Check Digit Verification of cas no
The CAS Registry Mumber 1081-05-6 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,0,8 and 1 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1081-05:
(6*1)+(5*0)+(4*8)+(3*1)+(2*0)+(1*5)=46
46 % 10 = 6
So 1081-05-6 is a valid CAS Registry Number.
1081-05-6Relevant articles and documents
Optimization of N-benzoylindazole derivatives as inhibitors of human neutrophil elastase
Crocetti, Letizia,Schepetkin, Igor A.,Cilibrizzi, Agostino,Graziano, Alessia,Vergelli, Claudia,Giomi, Donatella,Khlebnikov, Andrei I.,Quinn, Mark T.,Giovannoni, Maria Paola
, p. 6259 - 6272 (2013/09/02)
Human neutrophil elastase (HNE) is an important therapeutic target for treatment of pulmonary diseases. Previously, we identified novel N-benzoylindazole derivatives as potent, competitive, and pseudoirreversible HNE inhibitors. Here, we report further development of these inhibitors with improved potency, protease selectivity, and stability compared to our previous leads. Introduction of a variety of substituents at position 5 of the indazole resulted in the potent inhibitor 20f (IC50 ～10 nM) and modifications at position 3 resulted the most potent compound in this series, the 3-CN derivative 5b (IC50 = 7 nM); both derivatives demonstrated good stability and specificity for HNE versus other serine proteases. Molecular docking of selected N-benzoylindazoles into the HNE binding domain suggested that inhibitory activity depended on geometry of the ligand-enzyme complexes. Indeed, the ability of a ligand to form a Michaelis complex and favorable conditions for proton transfer between Hys57, Asp102, and Ser195 both affected activity.
